| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Lantern Pharma Inc. | LP-100 | Hormone-refractory prostate cancer (MHRPC) | Phase 2 | Trial Planned | Intravenous | Oncology |
| Lantern Pharma Inc. | LP-184 | Atypical Teratoid Rhabdoid Tumor (ATRT) | Phase 2 | Trial Planned | Intravenous | Oncology |
| Lantheus Holdings Inc. | Florquinitau (MK-6240) | Alzheimer's disease | PDUFA | Ongoing | Intravenous | Neurology |
| Lantheus Holdings Inc. | PYLARIFY (piflufolastat F 18) Injection | Prostate Cancer | PDUFA | Ongoing | Intravenous | Oncology |
| Lantheus Holdings Inc. | LNTH-2501 (Gallium-68 edotreotide) | Neuroendocrine tumors (NETs) in adult and pediatric patients | PDUFA | Ongoing | Intravenous | Oncology |
| Lantheus Holdings Inc. | Lutetium Lu 177 Dotatate (177Lu-PNT2003) | Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) | ANDA Filing | Intravenous | Oncology | |
| Lantheus Holdings Inc. | NAV-4694 - (F18-flutafuranol) | Alzheimer's disease | Phase 3 | Ongoing | Intravenous | Neurology |
| Lantheus Holdings Inc. | 177Lu-PNT2002 - (SPLASH) | Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Data Released | Intravenous | Oncology |